Mirati Therapeutics Inc.

(MRTX) Trade

By |

Profile

Mirati Therapeutics is an American biotechnology company. The company's medical focus is precision medicine: genetically targeted oncology therapeutics for selected patients. Mirati's drug candidates target specific genetic and epigenetic drivers of cancer. Its portfolio includes MGCD265, MGCD516, and mocetinostat. MGCD265 and MGCD516 are orally bioavailable inhibitors with distinct target profiles aiming to treat patients with non-small cell lung cancer and other solid tumors. MGCD265 and MGCD516 are in clinical development. Mocetinostat is an orally bioavailable, Class 1 selective histone deacetylase inhibitor in clinical development in collaboration with MedImmune, the global biologics research and development arm of AstraZeneca.

Contact Information

Website: www.mirati.com
Email: ir@mirati.com
Main Phone: +1 858 332-3410
Address: 9393 Towne Centre Drive
Address 2: Suite 200
State: CA
City / Town: San Diego
Country: USA
Postal Code: 92121

Issuer Information

Exchange: NGS
CEO: Charles M. Baum
Employees: 51
NAICS: Pharmaceutical Preparation Manufacturing(325412)


Gathering Data... Please wait

Profile

Mirati Therapeutics is an American biotechnology company. The company's medical focus is precision medicine: genetically targeted oncology therapeutics for selected patients. Mirati's drug candidates target specific genetic and epigenetic drivers of cancer. Its portfolio includes MGCD265, MGCD516, and mocetinostat. MGCD265 and MGCD516 are orally bioavailable inhibitors with distinct target profiles aiming to treat patients with non-small cell lung cancer and other solid tumors. MGCD265 and MGCD516 are in clinical development. Mocetinostat is an orally bioavailable, Class 1 selective histone deacetylase inhibitor in clinical development in collaboration with MedImmune, the global biologics research and development arm of AstraZeneca.

Contact Information

Website: www.mirati.com
Email: ir@mirati.com
Main Phone: +1 858 332-3410
Address: 9393 Towne Centre Drive
Address 2: Suite 200
State: CA
City / Town: San Diego
Country: USA
Postal Code: 92121

Issuer Information

Exchange: NGS
CEO: Charles M. Baum
Employees: 51
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 64.14 $ 1.67 (2.67%)
Last Price 64.14 Change $ 1.67 Change % 2.67 Tick N/A
Bid 55.35 Bid Size 100.00 Ask 72.58 Ask Size 100.00
Open 63.11 High 65.40 Low 62.95 Prev Close 62.47
Last Trade Volume 1.9 mi 52 Wk Hi 65.35 52 Wk Low 23.11
Market Cap 2.1 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 32,516,041.00 EPS (TTM) -2.96 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 4 49
Number of Buys 4 29
Number of Sells 0 20
Net Activity 13038 915424
Last 10 Buys Shares
Behzad Aghazadeh 1,000
Charles M. Baum 1,000
Julian C. Baker 1,000
Julian C. Baker 1,000
Last 10 Sell Shares
Jamie A. Donadio 1,000
James Christensen 1,000
Jamie A. Donadio 1,000
Jamie A. Donadio 1,000
Jamie A. Donadio 1,000
Charles M. Baum 1,000
Charles M. Baum 1,000
James Christensen 1,000
James Christensen 1,000
James Christensen 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 44 44 44 44
Low Target Price Estimate 30 30 30 30
Mean Target Price Estimate 38 38 38 38
Standard Deviation 5.1 5.1 5.1 5.1
Date of Most Recent Estimate 05/11/18 05/11/18 05/11/18 05/11/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 6 6 6 7
Moderate Buy 0 0 0 0
Hold 1 1 1 1
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.29 1.29 1.29 1.25